My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

51.78 -0.36 (-0.69%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

39 40 Next >

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space ↗

January 12, 2024

The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.

Via Investor's Business Daily

Sanofi's Olympic Endeavor: Leap Into Olympic Sponsorship Signals Cultural Transformation ↗

January 10, 2024

French pharmaceutical giant Sanofi SA (NASDAQ: SNY) is making an unconventional stride by sponsoring the 2024 Olympic Games in Paris in an effort to rejuvenate the company's image, attract a younger...

Via Benzinga

Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering ↗

January 05, 2024

Shares soared and then tumbled Friday after the company offered $275 million in public shares.

Via Investor's Business Daily

More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024 ↗

January 04, 2024

More than 140 brands of drugs are going to see their prices hiked heading into the new year

Via Talk Markets

China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants ↗

January 02, 2024

Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASD

Via Benzinga

Why NASDAQ:SNY is a Top Pick for Dividend Investors. ↗

January 02, 2024

Analyzing SANOFI-ADR (NASDAQ:SNY)'s Dividend Potential.

Via Chartmill

Looking Into Sanofi's Recent Short Interest ↗

December 21, 2023

Via Benzinga

Why NASDAQ:SNY provides a good dividend, while having solid fundamentals. ↗

December 12, 2023

Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals.

Via Chartmill

Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January ↗

December 29, 2023

Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on...

Via Benzinga

NASDAQ:SNY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

December 28, 2023

SANOFI-ADR (NASDAQ:SNY): good value for what you're paying.

Via Chartmill

Why First Wave BioPharma Shares Are Skyrocketing Today ↗

December 27, 2023

First Wave BioPharma, Inc. (NASDAQ: FWBI) shares are skyrocketing Wednesday after the company entered a non-binding term sheet to sell its Niclosamide program for the treatment of

Via Benzinga

Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today? ↗

December 21, 2023

MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson & Johnson (NYSE: JNJ) compan

Via Benzinga

European Drugmaker Sanofi Ends Tusamitamab Ravtansine Lung Cancer Program After Disappointing Data ↗

December 21, 2023

Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development pr

Via Benzinga

How Is The Market Feeling About Sanofi? ↗

November 30, 2023

Via Benzinga

First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline ↗

December 18, 2023

First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a pipeline for...

Via Benzinga

7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar ↗

December 17, 2023

While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.

Via InvestorPlace

It's Almost 2024: 3 Top Stocks to Buy Before the New Year ↗

December 17, 2023

You can pick these players up for a great price right now.

Via The Motley Fool

French Drugmaker Sanofi Secures European Medicines Agency's Positive Opinion For Sleeping Sickness Treatment ↗

December 15, 2023

Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium

Via Benzinga

3 Stocks to Buy Before 2024 That Can Set You Up For Life ↗

December 14, 2023

These stocks are still relatively cheap, but don't expect them to stay that way for long.

Via The Motley Fool

French Pharma Giant Sanofi Drops Rare Disease Drug Pact As Federal Trade Commission Puts Antitrust Obstacle ↗

December 12, 2023

Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic disorder after the Federal Trade Commission (FTC)

Via Benzinga

Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company ↗

December 07, 2023

Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S.

Via Benzinga

Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities ↗

December 07, 2023

Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbus

Via Benzinga

IGM Biosciences Increases Focus On Autoimmune Diseases, Stops All Blood Cancer-Related Studies ↗

December 06, 2023

IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies and treating autoimmune diseases using IgM...

Via Benzinga

Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis ↗

December 06, 2023

Merck KGaA (OTC: MKGAF) (OTC:

Via Benzinga

Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

December 06, 2023

SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift ↗

December 05, 2023

Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget.

Via Benzinga

Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers ↗

December 01, 2023

European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies...

Via Benzinga

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

November 30, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

November 30, 2023

These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.

Via The Motley Fool

Teva Pharma is the way to play the re-rise of generic drugs

November 28, 2023

Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth

Via MarketBeat

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

39 40 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.